ZEISS MEL 90 excimer laser receives U.S. FDA approval

ZEISS Medical Technology announced today that the MEL® 90 received approval from the U.S. Food and Drug Administration (FDA), giving the excimer laser technology simultaneous approval for all three major indications, including myopia, hyperopia and mixed astigmatism (a condition where both hyperopic and myopic correction is required). The ZEISS MEL 90 fully integrates into the Corneal Refractive Workflow to offer U.S. surgeons a fast, reliable, and streamlined surgery experience, complementing the VISUMAX® 800 with SMILE® pro from ZEISS to help further broaden a surgeon’s refractive business with improved patient attraction and positive clinical outcomes.

LabNews Media LLC

LabNews: Biotech. Digital Health. Life Sciences. Pugnalom: Environmental News. Nature Conservation. Climate Change. augenauf.blog: Wir beobachten Missstände

Vollständige Bio ansehen